What is the 13F Pro Quality Score for ALDX?

13F Pro ranks Aldeyra Therapeutics, Inc. (ALDX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ALDX's current score at https://13fpro.ai/research/ALDX (free sign-up required for the full ranking).

Which hedge funds own the most ALDX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of ALDX include Knoll Capital Management,, BlackRock,, AQR CAPITAL MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/ALDX as soon as new 13F filings post.

Where does 13F Pro source ALDX data?

All Aldeyra Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Aldeyra Therapeutics, Inc. files with the SEC under CIK 1341235. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ALDX in?

Aldeyra Therapeutics, Inc. (ALDX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ALDX research updated on 13F Pro?

ALDX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Aldeyra Therapeutics, Inc.(ALDX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1341235 ALDX stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

ALDX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Aldeyra Therapeutics, Inc. (ALDX), a Healthcare sector company. ALDX is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), Aldeyra Therapeutics, Inc. reports net income of $-3.5M, free cash flow of $-5.1M. Top institutional holders of ALDX by reported 13-F value include Knoll Capital Management,, BlackRock,, AQR CAPITAL MANAGEMENT, based on the most recent SEC filings. ALDX trades on the Nasdaq exchange and files with the SEC under CIK 1341235. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ALDX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Aldeyra Therapeutics, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-3.5M

Free Cash Flow

Q1 2026

$-5.1M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

-48.8% YoY

$-55.9MFY 2024

FY21 $-57.8MFY22 $-62.0MFY23 $-37.5MFY24 $-55.9M

Operating Income

-40.5% YoY

$-60.1MFY 2024

FY21 $-56.2MFY22 $-62.7MFY23 $-42.8MFY24 $-60.1M

EPS (Diluted)

-46.9% YoY

$-0.94FY 2024

FY21 $-1.07FY22 $-1.06FY23 $-0.64FY24 $-0.94

Total Assets

-29.5% YoY

$104.6MFY 2024

FY21 $233.1MFY22 $181.3MFY23 $148.3MFY24 $104.6M

Total Debt

-49.6% YoY

$15.3MFY 2024

FY21 $16.0MFY22 $17.2MFY23 $30.4MFY24 $15.3M

Op. Cash Flow

-42.5% YoY

$-43.2MFY 2024

FY21 $-42.6MFY22 $-56.6MFY23 $-30.3MFY24 $-43.2M

Metric	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Net Income	$-55.9M -48.8%	$-37.5M +39.5%	$-62.0M -7.4%	$-57.8M -53.8%	$-37.6M +38.3%	$-60.8M
Operating Income	$-60.1M -40.5%	$-42.8M +31.7%	$-62.7M -11.5%	$-56.2M -54.4%	$-36.4M +42.3%	$-63.1M
EPS (Diluted)	$-0.94 -46.9%	$-0.64 +39.6%	$-1.06 +0.9%	$-1.07	—	—
Total Assets	$104.6M -29.5%	$148.3M -18.2%	$181.3M -22.2%	$233.1M +179.7%	$83.4M +10.4%	$75.5M
Total Debt	$15.3M -49.6%	$30.4M +76.5%	$17.2M +7.5%	$16.0M +0.0%	$16.0M +0.0%	$16.0M
Operating Cash Flow	$-43.2M -42.5%	$-30.3M +46.5%	$-56.6M -33.1%	$-42.6M -13.5%	$-37.5M +16.7%	$-45.0M

AI Insight: ALDX Financial Trends

Aldeyra's net loss narrowed sharply to -$3M in Q1 2026 from -$17M in Q2 2024, signaling a major reduction in cash burn — but zero revenue and eroding equity remain critical concerns.

• Net loss compressed from -$17M in Q2 2024 to -$3M in Q1 2026, an 82% reduction over eight quarters.

• Operating cash outflow improved from -$13M in Q2 2024 to -$5M in Q1 2026, reflecting tighter cost discipline.

• Equity has declined every quarter, falling from $98M in Q2 2024 to $42M in Q1 2026 — a $56M erosion.

• Total debt rebounded to $30–31M by Q2 2025 after dropping to $15M in Q3–Q4 2024, suggesting new borrowing.

⚠ Revenue remains zero across all eight quarters; commercialization or partnership milestones are essential to solvency.

⚠ Equity at $42M and shrinking — at the current burn rate, dilution or additional debt financing appears imminent.

⚠ Debt held steady at $31M through Q4 2025 and Q1 2026; monitor covenant terms as equity cushion thins.

Get alerted when ALDX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Aldeyra Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ALDX

Knoll Capital Management, LLC
$9.3M5,475,516 sh
BlackRock, Inc.
$6.4M3,763,887 sh
AQR CAPITAL MANAGEMENT LLC
$4.8M2,829,875 sh
VANGUARD CAPITAL MANAGEMENT LLC
$4.0M2,363,742 sh
KINGDON CAPITAL MANAGEMENT, L.L.C.
$3.6M2,152,315 sh
683 Capital Management, LLC
$2.5M1,500,000 sh
D. E. Shaw & Co., Inc.
$2.4M1,403,990 sh
GEODE CAPITAL MANAGEMENT, LLC
$2.1M1,251,652 sh
STATE STREET CORP
$1.9M1,124,710 sh
MILLENNIUM MANAGEMENT LLC
$1.7M995,243 sh

Fund	Value	Shares
Knoll Capital Management, LLC	$9.3M	5,475,516
BlackRock, Inc.	$6.4M	3,763,887
AQR CAPITAL MANAGEMENT LLC	$4.8M	2,829,875
VANGUARD CAPITAL MANAGEMENT LLC	$4.0M	2,363,742
KINGDON CAPITAL MANAGEMENT, L.L.C.	$3.6M	2,152,315
683 Capital Management, LLC	$2.5M	1,500,000
D. E. Shaw & Co., Inc.	$2.4M	1,403,990
GEODE CAPITAL MANAGEMENT, LLC	$2.1M	1,251,652
STATE STREET CORP	$1.9M	1,124,710
MILLENNIUM MANAGEMENT LLC	$1.7M	995,243

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ALDX on your watchlist

Track score changes the day Aldeyra Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ALDX a good stock to buy?

13F Pro's AI-powered analysis of Aldeyra Therapeutics, Inc. (ALDX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ALDX are available on the ALDX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ALDX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ALDX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Aldeyra Therapeutics, Inc.'s investment landscape.